Παραιτήθηκε η πρόεδρος της Επιτροπής Τιμών Φαρμάκων

Σύμφωνα με πολύ καλά πληροφορημένες πηγές την παραίτησή της από τη θέση της προέδρου της Επιτροπής Τιμών Φαρμάκων υπέβαλε σήμερα το πρωί (Δευτέρας 7 Ιανουαρίου) η κ. Δέδε, μετά την απόρριψη της πρότασης της Επιτροπής για το διορθωτικό δελτίο τιμών φαρμάκων εκ μέρους του αναπληρωτή υπουργού Υγείας Μάριου Σαλμά.

Ο Μάριος Σαλμάς έχει προχωρήσει επίσης από την Παρασκευή 4 Ιανουαρίου σε αλλεπάλληλες "επικαιροποιήσεις" του διορθωτικού δελτίου για να καταλήξει τελικά στην ανάρτηση του... αρχικού διορθωτικού δελτίου τιμών φαρμάκων της 2ας Ιανουαρίου, για το οποίο ο Σύνδεσμος Φαρμακευτικών Επιχειρήσεων Ελλάδας (ΣΦΕΕ) έχει αποστείλει επιστολή διαμαρτυρίας στον αναπληρωτή υπουργό Υγείας.

What are the 7 mega-trends that will redefine the healthcare industry in 2013?

Deloitte Center for Health Solutions has created an interesting six-minute video in which Paul Keckley, the Center’s executive director, describes the seven mega-trends that will influence the healthcare industry in 2013.

All seven reinforce an undeniable reality — that business as usual won’t do — and present a “new normal.” It goes without saying that simply recognizing the mega-trends won’t do. Accepting them and changing is key. In other words, the dictum — using another well-worn cliche – is “change or die.”

Here are the mega-trends as defined by Keckley:

1. Demanding demographics: The U.S. population is changing — it’s more diverse and older than it used to be. There are also large income disparities within that population. The ability to access insurance and the desire to have more healthful lifestyles are creating the a unique set of demographics that is engaging with their healthcare and demanding more from the healthcare industry than previously.
2. Strategic globalization: U.S. companies involved in healthcare are looking to expand overseas. Not only is there inherent demand from the local population but medical tourism is on the rise: 25 percent of consumers report that they are willing to travel for a medical procedure. It’s important to look beyond U.S. borders for growth given projections like the U.S. share of global drug sales will drop 31 percent by 2015. And it’s not just pharma or device companies that need to look for growth in foreign soil, but insurance companies, providers, information technology companies as well.

Abbott, J&J, Sanofi Said to Show Bausch & Lomb Interest

Abbott Laboratories (ABT), Johnson & Johnson (JNJ) and Sanofi have shown interest in Bausch & Lomb Inc., the eye-care company Warburg Pincus LLC is seeking to sell, said people with knowledge of the matter.

Warburg, working with Goldman Sachs Group Inc., is giving interested parties access to its financial data and seeking first-round bids by month’s end, said the people, who asked not to be named because the process is private. Warburg is seeking at least $10 billion for the business, these people said. Goldman Sachs contacted some prospective bidders right before Christmas with information about Bausch & Lomb, said one of the people.